INmuneBIO: Funding, Investors & Team (Sep 2026)
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
INmuneBIO has raised $62.7M across 3 funding rounds on record, the most recent an undisclosed round of $13.0M announced in Sep 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
INmuneBIO Company Profile and Key Stats
Latest funding round on record: Sep 2024.
INmuneBIO Funding Rounds
INmuneBIO raised $40.0M in a Post-IPO Equity announced in Jul 2021.
2.8 years later, an undisclosed round of $9.7M was announced in Apr 2024.
5 months later, an undisclosed round of $13.0M was announced in Sep 2024.
INmuneBIO Founders and Leadership Team
Contact details for the INmuneBIO team: 3 of 4 have an email address on file.
Start 14-day free trial →INmuneBIO Funding Compared to Other Biotechnology Startups
INmuneBIO's latest round of $13.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like INmuneBIO in Biotechnology and La Jolla
Companies Similar to INmuneBIO
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
INmuneBIO Funding FAQs
What does INmuneBIO do?
INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
How much funding has INmuneBIO raised?
INmuneBIO has raised $62.7M across 3 rounds on record. The most recent is an undisclosed round of $13.0M announced in Sep 2024.
When did INmuneBIO last raise funding?
INmuneBIO's most recent funding round on record is an undisclosed round of $13.0M, announced in Sep 2024.
Who founded INmuneBIO?
FundedIQ lists Mark Lowdell (Founder), Raymond J Tesi (Founder) at INmuneBIO.
Who is the CEO of INmuneBIO?
Kelly Ganjei is listed as CEO at INmuneBIO.
Where is INmuneBIO headquartered?
INmuneBIO is based in La Jolla, California, United States.
How many employees does INmuneBIO have?
INmuneBIO is in the 11-50 employee band.
How does INmuneBIO's funding compare to other Biotechnology startups?
INmuneBIO's latest round of $13.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's INmuneBIO Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for INmuneBIO is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.